Reported 1 day ago
Leerink Partners has reiterated a Buy rating on MoonLake Immunotherapeutics (MLTX), with a price target of $73, emphasizing the potential of its drug Sonelokimab for treating hidradenitis suppurativa. Analyst Thomas Smith believes that the forthcoming Phase 3 VELA trial results will highlight the drug's effectiveness over existing treatments, likely leading to a significant increase in share price. Additionally, Smith's optimism is supported by favorable feedback from dermatology experts and the successful completion of patient enrollment in the trial.
Source: YAHOO